Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Expertise in Urinary Bladder Neoplasms: HELP
Allan J. Pantuck
Based on 11 articles published since 2008
||||
Expertise Level
The expertise of Allan J. Pantuck ranks in the Graphical view (beta)
Uncounted papers?
Aliases Pantuck, Allan J   ·   Pantuck, Allan
Work Locations
Details
Most likely:    UCLA   Contact    
2018
  • Division of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA. · David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA. · Institute of Urologic Oncology, Department of Urology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA. · Institute of Urologic Oncology, Department of Urology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA. · Division of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA; Institute of Urologic Oncology, Department of Urology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA. Electronic address: · Pubmed 29199023
  • Department of Urology, David Geffen School of Medicine at University of California, Los Angeles, USA. · Institute of Urologic Oncology, David Geffen School of Medicine at University of California, Los Angeles, USA. · , 300 Stein Plaza, Suite 348, Los Angeles, CA, 90095, USA. · Department of Urology, David Geffen School of Medicine at University of California, Los Angeles, USA. · Institute of Urologic Oncology, David Geffen School of Medicine at University of California, Los Angeles, USA. · Division of Hematology and Oncology, David Geffen School of Medicine at University of California, Los Angeles, USA. · Division of Urology, Department of Surgery, Harbor-UCLA Medical Center, Torrance, CA, USA. · Pubmed 29752514
  • Department of Urology, David Geffen School of Medicine at University of California, 300 Stein Plaza, Suite 348, Los Angeles, CA, 90095, USA. · Institute of Urologic Oncology, University of California, Los Angeles, USA. · Department of Hematology and Oncology, David Geffen School of Medicine at University of California, Los Angeles, USA. · Department of Urology, David Geffen School of Medicine at University of California, 300 Stein Plaza, Suite 348, Los Angeles, CA, 90095, USA. · Institute of Urologic Oncology, University of California, Los Angeles, USA. · Pubmed 29299664
2017
  • Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, CA. Electronic address: · Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, CA. · Division of Urology, Hahnemann University Hospital, Philadephia, PA. · Telormedix SA, Bioggio, Switzerland. · UroGen Pharma, Ra'anana, Israel. · The Urology Center of Colorado, Denver, CO. · BCG Oncology, Phoenix, AZ. · Carolina Urologic Research Center, Myrtle Beach, SC. · Pubmed 28341495
  • Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA. Electronic address: · Division of Laboratory and Animal Medicine, University of California, Los Angeles, Los Angeles, CA. · Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA. · UroGen Pharma Ltd., Ra'anana, Israel. · Department of Pathology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA. · Department of Radiology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA. · Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA. · Pubmed 27720772
2010
  • Department of Urology, University of California-Los Angeles, Los Angeles, California 90095-1738, USA. · Pubmed 20403620
2009
  • Department of Urology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California 90095-1738, USA. · Pubmed 19195047
2008
  • Department of Urology, David Geffen School of Medicine, University of California-Los Angeles, CA, USA. · Pubmed 18430124
  • David Geffen School of Medicine at UCLA, Los Angeles, CA 90025-1738, USA. · Pubmed 19035892
  • Department of Epidemiology, University of California at Los Angeles School of Public Health, 71-225 CHS, Box 951772, 650 Charles E. Young Drive South, Los Angeles, CA 90095-1772, USA. · Pubmed 18990762
Specific Interests

In the titles of their published articles, experts often reveal their very specific interests.

Here are the titles of the 10 most recent articles (out of 11 total) written by Allan J. Pantuck about Urinary Bladder Neoplasms:

  • Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma. 2018
  • The Current Status and Future Role of the Phosphoinositide 3 Kinase/AKT Signaling Pathway in Urothelial Cancer: An Old Pathway in the New Immunotherapy Era. 2018
  • Overall survival in patients with residual disease after radical cystectomy and neoadjuvant chemotherapy. 2018
  • Trends in urinary diversion after radical cystectomy for urothelial carcinoma. 2018
  • A phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancer. 2017
  • Sustained-release Formulation of Mitomycin C to the Upper Urinary Tract Using a Thermosensitive Polymer: A Preclinical Study. 2017
  • Absent CD44v6 expression is an independent predictor of poor urothelial bladder cancer outcome. 2010
  • Carbonic anhydrase IX in bladder cancer: a diagnostic, prognostic, and therapeutic molecular marker. 2009
  • The role of carbonic anhydrase IX as a molecular marker for transitional cell carcinoma of the bladder. 2008
  • Chemoprevention of bladder cancer. 2008
Show List of Full Article Records
Google Searches

Learn more about Allan J. Pantuck using the ready-made Google searches below.
This is essential! -- Publications never tell the whole story!

General Search:
UCLA
Affiliation Timeline
Click for institutional directory in table below. (Not always available.)
What is this?
UCLA
2018
  • Division of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA. · David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA. · Institute of Urologic Oncology, Department of Urology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA. · Institute of Urologic Oncology, Department of Urology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA. · Division of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA; Institute of Urologic Oncology, Department of Urology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA. Electronic address: · Pubmed 29199023
  • Department of Urology, David Geffen School of Medicine at University of California, Los Angeles, USA. · Institute of Urologic Oncology, David Geffen School of Medicine at University of California, Los Angeles, USA. · , 300 Stein Plaza, Suite 348, Los Angeles, CA, 90095, USA. · Department of Urology, David Geffen School of Medicine at University of California, Los Angeles, USA. · Institute of Urologic Oncology, David Geffen School of Medicine at University of California, Los Angeles, USA. · Division of Hematology and Oncology, David Geffen School of Medicine at University of California, Los Angeles, USA. · Division of Urology, Department of Surgery, Harbor-UCLA Medical Center, Torrance, CA, USA. · Pubmed 29752514
  • Department of Urology, David Geffen School of Medicine at University of California, 300 Stein Plaza, Suite 348, Los Angeles, CA, 90095, USA. · Institute of Urologic Oncology, University of California, Los Angeles, USA. · Department of Hematology and Oncology, David Geffen School of Medicine at University of California, Los Angeles, USA. · Department of Urology, David Geffen School of Medicine at University of California, 300 Stein Plaza, Suite 348, Los Angeles, CA, 90095, USA. · Institute of Urologic Oncology, University of California, Los Angeles, USA. · Pubmed 29299664
2017
  • Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, CA. Electronic address: · Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, CA. · Division of Urology, Hahnemann University Hospital, Philadephia, PA. · Telormedix SA, Bioggio, Switzerland. · UroGen Pharma, Ra'anana, Israel. · The Urology Center of Colorado, Denver, CO. · BCG Oncology, Phoenix, AZ. · Carolina Urologic Research Center, Myrtle Beach, SC. · Pubmed 28341495
  • Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA. Electronic address: · Division of Laboratory and Animal Medicine, University of California, Los Angeles, Los Angeles, CA. · Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA. · UroGen Pharma Ltd., Ra'anana, Israel. · Department of Pathology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA. · Department of Radiology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA. · Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA. · Pubmed 27720772
2010
  • Department of Urology, University of California-Los Angeles, Los Angeles, California 90095-1738, USA. · Pubmed 20403620
2009
  • Department of Urology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California 90095-1738, USA. · Pubmed 19195047
2008
  • Department of Urology, David Geffen School of Medicine, University of California-Los Angeles, CA, USA. · Pubmed 18430124
  • David Geffen School of Medicine at UCLA, Los Angeles, CA 90025-1738, USA. · Pubmed 19035892
  • Department of Epidemiology, University of California at Los Angeles School of Public Health, 71-225 CHS, Box 951772, 650 Charles E. Young Drive South, Los Angeles, CA 90095-1772, USA. · Pubmed 18990762
Unspecified
2018
  • Department of Urology. · Institute of Urologic Oncology. · Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine at University of California, Los Angeles, CA, USA. · Pubmed 29416316
Yearly article counts 042000000113
Remember this Person You can save this page -- like a bookmark -- so it's remembered for you on the Expertscape "Saved Pages" page, which is always easily available from the page-top menu bar throughout the site.